GSK's New Vaccine Kept the Boss in Her Job — and an A

(Bloomberg) -- When Elliott Investment Management came calling for the ouster of Emma Walmsley, the chief executive officer of GSK Plc found her remedy in a product almost 60 years in the making.Most Read from BloombergHims Debuts $199 Weight-Loss Shots at 85% Discount to WegovyIran State TV Says ‘No Sign of Life’ at Helicopter Crash SiteJamie Dimon Says Succession at JPMorgan Is ‘Well on the Way’One of the Last Big Bears on Wall Street Turns Bullish on US StocksFlorida’s 125% Surge in Property-

Related Keywords

United Kingdom , London , City Of , Stevenage , Hertfordshire , Britain , Alex Chajecki , Philip Hampton , Jon Symonds , Swetha Gopinath , Emma Walmsley , Alisa Pham , Berkeley Square , Richard Kramer , Tony Wood , Bloomberg Businessweek , Christi Kelsey , Luke Miels , Julie Brown , Britain Royal Navy , Bloomberg , Barclays , Pfizer , Pfizer Inc , Health Corp , Astrazeneca Plc , Goodyear Tire Rubber Co , Johnson , Haleon Plc , Tesaro Inc , Candel Therapeutics Inc , Elliott Investment Management , Goodyear Tire , Royal Navy , Chairman Jon Symonds , Gordon Singer , Emily Field , Commercial Officer Luke Miels , Scientific Officer Tony Wood , Peter Tak ,